Literature DB >> 3354777

The case for selective cholangiography.

R O Gregg1.   

Abstract

Seven hundred sixty-five patients were operated on in two hospitals in 1979 and 1980, 190 of whom were submitted to operative cholangiography, 41 to primary common duct exploration, and 534 to neither. The incidence of common duct stones was 4 percent in the minimal indications group, 21 percent in the moderate indications group, and 91 percent in the maximal indications group. Follow-up of 5 years revealed 1 recurrence in the minimal group subjected to cholangiography and none among the 534 in whom no cholangiogram was obtained. In the period from 1981 through 1985, eight patients returned with common duct stones, having had no common duct stones at the primary operation. In the same period, 1,722 of 2,533 patients were operated on without cholangiography. The ratio of recurrences to primary operations without cholangiography was 1:225 or 0.45 percent. From these findings, we conclude that on the basis of cost-effectiveness and insurance against subsequent disease and disability, cholangiography is only indicated in patients with moderate indications (minimal jaundice, moderately dilated common duct, pancreatitis, or an increased serum amylase level). Cholangiography is not indicated if there are no indications of obstruction of the common duct by stones (as a routine for small stones in the gallbladder, if the cystic duct is patent, or if there is an isolated increased serum alkaline phosphatase level). Cholangiography is also unnecessary, when the indications of common duct stones are maximal (deep jaundice, huge common duct, cholangitis, or palpable stone). In our geographic area, intraoperative cholangiography should be selected in 7 to 8 percent of patients.

Entities:  

Mesh:

Year:  1988        PMID: 3354777     DOI: 10.1016/s0002-9610(88)80406-9

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  17 in total

1.  Routine versus selective intra-operative cholangiography during laparoscopic cholecystectomy.

Authors:  N J Soper; D L Dunnegan
Journal:  World J Surg       Date:  1992 Nov-Dec       Impact factor: 3.352

2.  Routine fluoroscopic cholangiography during laparoscopic cholecystectomy: an argument.

Authors:  E W Bruhn; F J Miller; J G Hunter
Journal:  Surg Endosc       Date:  1991       Impact factor: 4.584

3.  Acute upper gastrointestinal hemorrhage caused by gallstone impaction in the duodenal bulb.

Authors:  R L Heyd; M R Solinger; A L Howard; J C Rosser
Journal:  Dig Dis Sci       Date:  1992-03       Impact factor: 3.199

4.  Laparoscopy in General Surgery: The pros and cons of endoscopic surgery.

Authors:  P J O'Regan; D L Anderson
Journal:  Can Fam Physician       Date:  1992-07       Impact factor: 3.275

Review 5.  General surgery.

Authors:  I Taylor
Journal:  Postgrad Med J       Date:  1990-05       Impact factor: 2.401

Review 6.  Utility of fluorescent cholangiography during laparoscopic cholecystectomy: A systematic review.

Authors:  Antonio Pesce; Gaetano Piccolo; Gaetano La Greca; Stefano Puleo
Journal:  World J Gastroenterol       Date:  2015-07-07       Impact factor: 5.742

7.  Intraoperative cholangiography during laparoscopic cholecystectomy. Routine vs selective policy.

Authors:  A Cuschieri; S Shimi; S Banting; L K Nathanson; A Pietrabissa
Journal:  Surg Endosc       Date:  1994-04       Impact factor: 4.584

8.  Laparoscopic cholecystectomy: experience of a single surgeon.

Authors:  N J Soper; D L Dunnegan
Journal:  World J Surg       Date:  1993 Jan-Feb       Impact factor: 3.352

9.  Assessment of the common bile duct before cholecystectomy using ultrasound and biochemical measurements: validation based on follow-up.

Authors:  D S Watkin; J M Haworth; D J Leaper; M H Thompson
Journal:  Ann R Coll Surg Engl       Date:  1994-09       Impact factor: 1.891

10.  Laparoscopic cholangiography. Results and indications.

Authors:  J L Flowers; K A Zucker; S M Graham; W A Scovill; A L Imbembo; R W Bailey
Journal:  Ann Surg       Date:  1992-03       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.